JP4377266B2 - Collagen synthesis promoter and anti-aging cosmetic - Google Patents
Collagen synthesis promoter and anti-aging cosmetic Download PDFInfo
- Publication number
- JP4377266B2 JP4377266B2 JP2004077538A JP2004077538A JP4377266B2 JP 4377266 B2 JP4377266 B2 JP 4377266B2 JP 2004077538 A JP2004077538 A JP 2004077538A JP 2004077538 A JP2004077538 A JP 2004077538A JP 4377266 B2 JP4377266 B2 JP 4377266B2
- Authority
- JP
- Japan
- Prior art keywords
- collagen synthesis
- collagen
- skin
- oryzanol
- synthesis promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000008186 Collagen Human genes 0.000 title claims description 44
- 108010035532 Collagen Proteins 0.000 title claims description 44
- 229920001436 collagen Polymers 0.000 title claims description 44
- 230000015572 biosynthetic process Effects 0.000 title claims description 31
- 238000003786 synthesis reaction Methods 0.000 title claims description 29
- 230000003712 anti-aging effect Effects 0.000 title claims description 10
- 239000002537 cosmetic Substances 0.000 title claims description 6
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 claims description 20
- RRTBTJPVUGMUNR-UHFFFAOYSA-N Cycloartanol Natural products C12CCC(C(C(O)CC3)(C)C)C3C2(CC)CCC2(C)C1(C)CCC2C(C)CCCC(C)C RRTBTJPVUGMUNR-UHFFFAOYSA-N 0.000 claims description 6
- YNBJLDSWFGUFRT-UHFFFAOYSA-N cycloartenol Natural products CC(CCC=C(C)C)C1CCC2(C)C1(C)CCC34CC35CCC(O)C(C)(C)C5CCC24C YNBJLDSWFGUFRT-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- XZEUYTKSAYNYPK-UHFFFAOYSA-N 3beta-29-Norcycloart-24-en-3-ol Natural products C1CC2(C)C(C(CCC=C(C)C)C)CCC2(C)C2CCC3C(C)C(O)CCC33C21C3 XZEUYTKSAYNYPK-UHFFFAOYSA-N 0.000 claims description 3
- CIBNJPPYSPYHDB-UHFFFAOYSA-N Cyclobranol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCC(C)=C(C)C)C)CCC3(C)C1CC2 CIBNJPPYSPYHDB-UHFFFAOYSA-N 0.000 claims description 3
- HVXLSFNCWWWDPA-UHFFFAOYSA-N Isocycloartenol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCCC(C)=C)C)CCC3(C)C1CC2 HVXLSFNCWWWDPA-UHFFFAOYSA-N 0.000 claims description 3
- HXQRIQXPGMPSRW-UHZRDUGNSA-N Pollinastanol Natural products O[C@@H]1C[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@H]([C@H](CCCC(C)C)C)CC5)CC4)CC2)C3)CC1 HXQRIQXPGMPSRW-UHZRDUGNSA-N 0.000 claims description 3
- YABASAWVVRQMEU-YBXTVTTCSA-N cycloartanol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]3(C)[C@@H]1CC2 YABASAWVVRQMEU-YBXTVTTCSA-N 0.000 claims description 3
- ONQRKEUAIJMULO-YBXTVTTCSA-N cycloartenol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@@]3(C)[C@@H]1CC2 ONQRKEUAIJMULO-YBXTVTTCSA-N 0.000 claims description 3
- FODTZLFLDFKIQH-UHFFFAOYSA-N cycloartenol trans-ferulate Natural products C1=C(O)C(OC)=CC(C=CC(=O)OC2C(C3CCC4C5(C)CCC(C5(C)CCC54CC53CC2)C(C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-UHFFFAOYSA-N 0.000 claims description 3
- CIBNJPPYSPYHDB-UEBIAWITSA-N cyclobranol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CCC(C)=C(C)C)C)CC[C@@]3(C)[C@@H]1CC2 CIBNJPPYSPYHDB-UEBIAWITSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 description 15
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000008213 purified water Substances 0.000 description 7
- 230000037303 wrinkles Effects 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000863032 Trieres Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical class C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、γ−オリザノール加水分解物からなるコラーゲン合成促進剤に関するものであり、更には、このコラーゲン合成促進剤を含有する抗老化用化粧料に関するものである。 The present invention relates to a collagen synthesis accelerator comprising a γ-oryzanol hydrolyzate, and further relates to an anti-aging cosmetic containing this collagen synthesis accelerator.
皮膚は、常に外界にさらされており、加齢とともにシワ、タルミ、くすみ、色素沈着などが生じる。なかでも、シワやタルミといった形態変化は、真皮マトリックスの９０％以上を占めるコラーゲンによる影響が大きいと考えられている。真皮コラーゲンの量は、加齢と共に減少し、この減少は、若者に比べ約２０％の皮膚の厚さの減少となり、コラーゲンの減少で真皮構造の形成が不完全になるため、皮膚はもろくなる。また、光老化皮膚のコラーゲン量も、通常の皮膚に比べ、著しくコラーゲン量は減少しており、シワ、タルミの大きな形成要因として考えられている。 The skin is always exposed to the outside world, and wrinkles, tarmi, dullness, pigmentation, etc. occur with aging. Among these, morphological changes such as wrinkles and tarmi are considered to be greatly influenced by collagen that accounts for 90% or more of the dermal matrix. The amount of dermal collagen decreases with aging, and this decrease is about 20% less skin thickness than adolescents, and the skin becomes brittle because the decrease in collagen causes incomplete formation of the dermal structure. . In addition, the amount of collagen in photoaged skin is remarkably reduced as compared with that of normal skin, and it is considered as a major cause of formation of wrinkles and tarmi.
皮膚の加齢による形態変化を予防する薬剤としてレチノ−ルやレチノイン酸誘導体が、コラーゲン合成を促進するシワ防止化粧品として用いられている。しかし、これらの薬剤は、皮膚刺激性が強く、更には、非常に不安定な物質であり、特殊な製剤化技術を必要とされる。（例えば、特許文献１や特許文献２）他には、ビタミンＣ誘導体が、コラーゲン合成促進効果を持った薬剤として知られているが、経時的な着色や安定性の問題から、処方上の制約があり、使用者の希望を充分に満足させるものにはなり得なかった。
本発明者等は、皮膚における線維芽細胞のコラーゲン量は、若々しい肌を保つ上で重要な意味があると考え、コラーゲン合成促進剤を開発する事、および、コラーゲン合成促進剤を配合したシワ改善効果を有する抗老化用化粧料を提供することを課題とした。 The present inventors considered that the amount of fibroblast collagen in the skin has an important meaning in maintaining youthful skin, and developed a collagen synthesis promoter and formulated a collagen synthesis promoter. An object of the present invention is to provide an anti-aging cosmetic having a wrinkle improving effect.
本発明者は、前記の課題を解決するため、鋭意検討を行った結果、γ−オリザノール加水分解物に、コラーゲン合成促進作用を有することを見出し、本発明を完成するに至った。 As a result of intensive studies in order to solve the above-mentioned problems, the present inventor has found that γ-oryzanol hydrolyzate has an action of promoting collagen synthesis, and has completed the present invention.
本発明の、γ−オリザノール加水分解物からなるコラーゲン合成促進剤、あるいは、γ−オリザノール加水分解物を有効成分として含有するコラーゲン合成促進剤は、皮膚の線維芽細胞においてコラーゲン合成促進効果を有する。これらのコラーゲン合成促進剤は、皮膚における線維芽細胞のコラーゲン量を多くすることができ、結果として、シワの改善効果を示し、抗老化用化粧料の有効成分として使用することができる。 The collagen synthesis promoter comprising γ-oryzanol hydrolyzate or the collagen synthesis promoter containing γ-oryzanol hydrolyzate as an active ingredient has an effect of promoting collagen synthesis in skin fibroblasts. These collagen synthesis promoters can increase the amount of fibroblast collagen in the skin, and as a result, show an effect of improving wrinkles and can be used as an active ingredient in anti-aging cosmetics.
本発明の、γ−オリザノール加水分解物は、γ−オリザノールを加水分解して生成するトリテルペンアルコールを示し、シクロアルタノールやシクロアルテノールやシクロブラノールなどのことであり、市販のγ−オリザノールをケン化分解し、エーテルなどで抽出することで得られる。 The hydrolyzate of γ-oryzanol of the present invention indicates triterpene alcohol produced by hydrolyzing γ-oryzanol, such as cycloartanol, cycloartenol, cyclobranol, etc. It can be obtained by saponification decomposition and extraction with ether.
本発明のγ−オリザノール加水分解物は、後で証明するように、コラーゲン合成促進機能を有する。したがって、コラーゲン合成促進剤として有用である。 As will be demonstrated later, the γ-oryzanol hydrolyzate of the present invention has a function of promoting collagen synthesis. Therefore, it is useful as a collagen synthesis promoter.
本発明のコラーゲン合成促進剤であるγ−オリザノール加水分解物は、有効成分として含有されコラーゲン合成促進剤として応用される他、皮膚外用剤に配合して、皮膚の線維芽細胞においてコラーゲン合成促進作用を発揮して、コラーゲン合成促進作用によるシワの改善効果等の抗老化作用の機能を持つ、抗老化用皮膚外用剤などに調製することができる。 The γ-oryzanol hydrolyzate, which is a collagen synthesis promoter of the present invention, is contained as an active ingredient and applied as a collagen synthesis promoter. In addition, it is added to a skin external preparation to promote collagen synthesis in skin fibroblasts. Thus, it can be prepared as an anti-aging skin external preparation or the like having a function of anti-aging action such as wrinkle improvement effect by collagen synthesis promoting action.
本発明のγ−オリザノール加水分解物を皮膚外用剤に配合して使用する場合のγ−オリザノール加水分解物の配合量は、皮膚外用剤全量中０．０００１〜１０重量％、好ましくは、０．００１〜２重量％である。 When the γ-oryzanol hydrolyzate of the present invention is used by blending with a skin external preparation, the amount of γ-oryzanol hydrolyzate is 0.0001 to 10% by weight, preferably 0. 001 to 2% by weight.
本発明の皮膚外用剤は、外用剤基剤に通常用いられる油脂類、エステル油類、炭化水素油類、ロウ類、低級アルコール類、高級アルコール類、多価アルコール類、脂肪酸類、界面活性剤、水溶性高分子類、香料、水等を適宜配合することができ、更に他の老化防止剤、保湿剤、育毛剤、発毛剤、経皮吸収促進剤、紫外線吸収剤、細胞賦活剤、抗炎症剤、美白剤、防腐防カビ剤などを配合することが出来る。 The external preparation for skin of the present invention comprises oils, ester oils, hydrocarbon oils, waxes, lower alcohols, higher alcohols, polyhydric alcohols, fatty acids, surfactants that are usually used for external preparation bases. , Water-soluble polymers, fragrances, water, etc. can be appropriately blended, and further anti-aging agent, moisturizer, hair restorer, hair growth agent, percutaneous absorption enhancer, ultraviolet absorber, cell activator, Anti-inflammatory agents, whitening agents, antiseptics and fungicides can be added.
以下、本発明の内容を実施例により更に説明する。
（実施例１）
Hereinafter, the contents of the present invention will be further described with reference to examples.
Example 1
線維芽細胞によるコラーゲン合成能の評価
線維芽細胞は５％子牛血清（ＦＢＳ）含有ＤＭＥＭを用いて９６穴マイクロプレートにほぼコンフルエントになるように播種し、播種２４時間後に所定の濃度の試料を含有した０．５％ＦＢＳ含有ＤＭＥＭと交換した。陽性コントロールとして５０?Ｍアスコルビン酸リン酸マグネシウムを用いた。４８時間、試料含有培地で培養したのち、培地を回収してＥＬＩＳＡに供した。細胞は０．１％ Ｔｒｉｔｏｎ Ｘ−１００溶液にて溶解したのち、Ｌｏｗｒｙ法を用いてタンパク量を定量した。コラーゲンのＥＬＩＳＡは直接法で実施した。すなわち、培地および検量線用コラーゲンをＳＵＭＩＬＯＮ ＭＵＬＴＩ ＷＥＬＬ ＰＬＡＴＥ Ｈ Ｔｙｐｅ Ｐｌａｔｅ （住友ベークライト）に入れ、４℃にて一昼夜コーティングしたのち、１％牛血清アルブミン（ＢＳＡ）溶液を用いて３７℃にて１時間ブロッキングした。一次抗体として、Ａｎｔｉ−Ｈｕｍａｎ Ｃｏｌｌａｇｅｎ Ｔｙｐｅ Ｉ ａｎｔｉｂｏｄｙ（Ｒａｂｂｉｔ）を用い、０．３％ＢＳＡ溶液で希釈した一次抗体を３７℃にて１時間反応させた。二次抗体として、ヒストファインＰＯ（Ｒａｂｂｉｔ）を用い、０．３％ＢＳＡ溶液で１００倍希釈した二次抗体を３７℃にて１時間反応させた。Ｐｅｒｏｘｉｄａｓｅの発色試薬として２，２'−Ａｚｉｎｏｂｉｓ（３−ｅｔｈｙｌｂｅｎｚｏｔｈｉａｚｏｌｉｎｅ−６−ｓｕｌｆｏｎｉｃ ａｃｉｄ）ｄｉａｍｍｏｕｎｉｕｍ ｓａｌｔ （ＡＢＴＳ）を用い、０．３ｍｇ／ｍｌのリン酸−クエン酸バッファー（０．１Ｍ， ｐＨ４．０） 溶液を加え、２０分間反応させ、マイクロプレートリーダーにて４０５ｎｍの吸光度を測定した。
Evaluation of collagen synthesis ability by fibroblasts Fibroblasts were seeded in a 96-well microplate so as to be almost confluent using DMEM containing 5% calf serum (FBS), and a sample with a predetermined concentration was seeded 24 hours after sowing. It was replaced with 0.5% FBS-containing DMEM. 50-M magnesium ascorbate phosphate was used as a positive control. After culturing in a sample-containing medium for 48 hours, the medium was collected and subjected to ELISA. The cells were lysed with 0.1% Triton X-100 solution, and the amount of protein was quantified using the Lowry method. Collagen ELISA was performed by the direct method. That is, the medium and the calibration curve collagen were placed in SUMILON MULTI WELL PLATE H Type Plate (Sumitomo Bakelite), coated at 4 ° C overnight, and then 1% bovine serum albumin (BSA) solution at 37 ° C for 1 hour. Blocked. Anti-Human Collagen Type I antibody (Rabbit) was used as the primary antibody, and the primary antibody diluted with 0.3% BSA solution was reacted at 37 ° C. for 1 hour. As a secondary antibody, Histofine PO (Rabbit) was used, and a secondary antibody diluted 100-fold with a 0.3% BSA solution was reacted at 37 ° C. for 1 hour. 2,2′-Azinobis (3-ethylbenzothizoline-6-sulfonic acid) diammonium salt (ABTS) was used as a coloring reagent for Peroxidase, and 0.3 mg / ml phosphate-citrate buffer (0.1 M, pH 4.0) The solution was added, reacted for 20 minutes, and the absorbance at 405 nm was measured with a microplate reader.
培地中のコラーゲン含有量は、同じプレートで測定した検量線から算出した。
Ｌｏｗｒｙ法によって測定した全細胞のタンパク量で、ＥＬＩＳＡを用いて測定した培地中のコラーゲン含有量を除することによって、細胞の単位タンパク量あたりのコラーゲン産生量を算出した。
Collagen content in the medium was calculated from a calibration curve measured on the same plate.
The amount of collagen produced per unit protein amount of the cell was calculated by dividing the collagen content in the medium measured using ELISA by the protein amount of all cells measured by the Lowry method.
コラーゲン産生量（ｎｇ／ｍｇ ｐｒｏｔｅｉｎ）＝培地中のコラーゲン含有量（ｎｇ／ｗｅｌｌ）÷全タンパク量（ｍｇ／ｗｅｌｌ） Collagen production (ng / mg protein) = collagen content in medium (ng / well) ÷ total protein (mg / well)
コラーゲン合成能は、試料を添加せずに培養した細胞（コントロール）のコラーゲン産生量を１００として、各濃度の試料で培養した時のコラーゲン産生量の割合（％）であらわした。 Collagen synthesis ability was expressed as a percentage (%) of the amount of collagen produced when the cells were cultured in each concentration sample, with the amount of collagen produced by the cells cultured without adding the sample (control) as 100.
（試験結果）
評価結果を表１に示した。表１の結果より、γ‐オリザノ−ル加水分解物は、未添加の場合と比べて、明らかにコラーゲン合成能が増大した。
(Test results)
The evaluation results are shown in Table 1. From the results in Table 1, the γ-oryzanol hydrolyzate clearly increased the ability to synthesize collagen as compared to the case where it was not added.
このことから、γ−オリザノール加水分解物は、有効成分として含有されコラーゲン合成促進剤として応用される他、皮膚外用剤に配合して、皮膚の線維芽細胞においてコラーゲン合成促進作用を発揮して、コラーゲン合成促進作用によるシワの改善効果等の抗老化作用の機能を持つ、抗老化用皮膚外用剤として有用であることが分かる。
From this, γ-oryzanol hydrolyzate is contained as an active ingredient and applied as a collagen synthesis promoter, and is added to a skin external preparation to exert a collagen synthesis promoting action in skin fibroblasts. It turns out that it is useful as a skin external preparation for anti-aging which has the function of anti-aging effects, such as a wrinkle improvement effect by collagen synthesis promotion action.
以下に、本発明のコラーゲン合成促進剤を配合した皮膚外用剤の応用例を示す。配合量は重量％である。 Below, the example of application of the skin external preparation which mix | blended the collagen synthesis promoter of this invention is shown. The blending amount is% by weight.
処方例１ アイゲル
（Ａ）
γ−オリザノール加水分解物 ０．２％
精製水素添加大豆リン脂質 １．０％
精製オリーブスクワラン １０．０％
テトラエチルヘキサン酸ペンタエリスリチル ６．０％
プロピルパラベン ０．２％
（Ｂ）
アクリレーツ／アクリル酸アルキル（Ｃ１０−３０）
クロスポリマー２％水溶液 １５．０％
キサンタンガム２％水溶液 １０．０％
精製水 １４．４％
（Ｃ）
ヒアルロン酸ナトリウム１％水溶液 １．０％
１，３−ブチレングリコール ７．０％
メチルパラベン ０．２％
精製水 ３０．０％
（Ｄ）
アルギニン ０．２％
精製水 ４．８％
調整法
Ａ、Ｂ、Ｃをそれぞれ８０℃に加熱し、均一に溶解した。ＣにＢを加え混合した後に、Ａを添加した。撹拌しながら冷却し、５０℃でＤを添加し、３５℃で調製を終了した。
Formulation Example 1 Eye Gel (A)
γ-Oryzanol hydrolyzate 0.2%
Purified hydrogenated soybean phospholipid 1.0%
Refined olive squalane 10.0%
Pentaerythrityl tetraethylhexanoate 6.0%
Propylparaben 0.2%
(B)
Acrylates / alkyl acrylate (C10-30)
Cross polymer 2% aqueous solution 15.0%
Xanthan gum 2% aqueous solution 10.0%
Purified water 14.4%
(C)
Sodium hyaluronate 1% aqueous solution 1.0%
1,3-butylene glycol 7.0%
Methylparaben 0.2%
Purified water 30.0%
(D)
Arginine 0.2%
Purified water 4.8%
Preparation methods A, B and C were each heated to 80 ° C. and dissolved uniformly. After adding B to C and mixing, A was added. The mixture was cooled with stirring, D was added at 50 ° C, and the preparation was completed at 35 ° C.
処方例２ アイクリーム１
（Ａ）
γ−オリザノール加水分解物 ２．０％
精製水素添加大豆リン脂質 ０．５％
ミリスチン酸デカグリセリル ３．０％
セラキルアルコール ２．０％
パルミチン酸セチル ４．０％
精製オリーブスクワラン １０．０％
トリエ２−エチルヘキサン酸グリセリル ８．０％
セタノール ６．０％
プロピルパラベン ０．２％
（Ｂ）
グリセリン ３．０％
キサンタンガム２％水溶液 １０．０％
メチルパラベン ０．２％
精製水 ５１．１％
調整法
Ａ、Ｂをそれぞれ８０℃に加熱し、均一に溶解した。ホモミキサーでＡを撹拌しながら混合しＢを添加して乳化後、パドル撹拌しながら冷却し、３５℃で調製を終了した。
Formulation Example 2 Eye Cream 1
(A)
γ-Oryzanol hydrolyzate 2.0%
Purified hydrogenated soybean phospholipid 0.5%
Decaglyceryl myristate 3.0%
Serakil alcohol 2.0%
Cetyl palmitate 4.0%
Refined olive squalane 10.0%
Trier 2-glyceryl ethylhexanoate 8.0%
Cetanol 6.0%
Propylparaben 0.2%
(B)
Glycerol 3.0%
Xanthan gum 2% aqueous solution 10.0%
Methylparaben 0.2%
Purified water 51.1%
Preparation methods A and B were each heated to 80 ° C. and dissolved uniformly. A was mixed with stirring with a homomixer, B was added and emulsified, then cooled with paddle stirring, and the preparation was completed at 35 ° C.
処方例３ アイクリーム２
（Ａ）
γ−オリザノール加水分解物 ０．１％
ステアリン酸グリセリル ５．０％
ＰＯＥ（２５）セチルエーテル １．５％
トリ（カプリル酸／カプリン酸）グリセリル ７．０％
セタノール ５．０％
プロピルパラベン ０．２％
（Ｂ）
１，３−ブチレングリコール １．５％
メチルパラベン ０．２％
精製水 ５９．３％
（Ｃ）
キサンタンガム２％水溶液 １０．０％
エデト酸ニナトリウム ０．２％
精製水 １０．０％
調整法
Ａ、Ｂをそれぞれ８０℃に加熱し、均一に溶解した。ＡにＢを添加して乳化した後、撹拌冷却しながら５０℃でＣを添加し、３５℃で調製を終了した。
Formulation Example 3 Eye Cream 2
(A)
γ-Oryzanol hydrolyzate 0.1%
Glyceryl stearate 5.0%
POE (25) cetyl ether 1.5%
Tri (caprylic / capric) glyceryl 7.0%
Cetanol 5.0%
Propylparaben 0.2%
(B)
1,3-butylene glycol 1.5%
Methylparaben 0.2%
Purified water 59.3%
(C)
Xanthan gum 2% aqueous solution 10.0%
Edetate disodium 0.2%
Purified water 10.0%
Preparation methods A and B were each heated to 80 ° C. and dissolved uniformly. After emulsification by adding B to A, C was added at 50 ° C. with stirring and cooling, and the preparation was completed at 35 ° C.
処方例４ 化粧水
（Ａ）
γ−オリザノール加水分解物 ０．２％
ＰＯＥ（４０）硬化ヒマシ油 １．５％
１，３−ブチレングリコール ５．０％
ジプロピレングリコール ５．０％
メチルパラベン ０．２％
（Ｂ）
カミツレエキス ０．２％
ヒアルロン酸ナトリウム１％水溶液 ５．０％
精製水 ８２．９％
調整法
Ａを７０℃で加温し均一にした。Ｂは室温で均一混合した。Ａを撹拌しながら室温下にてＢを少しずつ加え、可溶化した。
Formulation Example 4 Lotion (A)
γ-Oryzanol hydrolyzate 0.2%
POE (40) hydrogenated castor oil 1.5%
1,3-butylene glycol 5.0%
Dipropylene glycol 5.0%
Methylparaben 0.2%
(B)
Chamomile extract 0.2%
Sodium hyaluronate 1% aqueous solution 5.0%
Purified water 82.9%
Preparation method A was heated at 70 ° C. to make it uniform. B was uniformly mixed at room temperature. While stirring A, B was added little by little at room temperature to solubilize.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004077538A JP4377266B2 (en) | 2004-03-18 | 2004-03-18 | Collagen synthesis promoter and anti-aging cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004077538A JP4377266B2 (en) | 2004-03-18 | 2004-03-18 | Collagen synthesis promoter and anti-aging cosmetic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005263677A JP2005263677A (en) | 2005-09-29 |
| JP4377266B2 true JP4377266B2 (en) | 2009-12-02 |
Family
ID=35088587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004077538A Expired - Lifetime JP4377266B2 (en) | 2004-03-18 | 2004-03-18 | Collagen synthesis promoter and anti-aging cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4377266B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4965807B2 (en) * | 2005-03-30 | 2012-07-04 | 日光ケミカルズ株式会社 | Composition for external use and external preparation for skin containing the same |
| WO2011061932A1 (en) | 2009-11-18 | 2011-05-26 | 株式会社ロッテ | Ceramide and collagen synthesis promoter and collagen saccharification inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5967211A (en) * | 1982-10-12 | 1984-04-16 | Kazuo Suga | Cosmetic composition |
| JPH05310526A (en) * | 1992-05-07 | 1993-11-22 | Eisai Co Ltd | Cell differentiation promotor |
-
2004
- 2004-03-18 JP JP2004077538A patent/JP4377266B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005263677A (en) | 2005-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6753000B2 (en) | Hydroxystilbene/ascorbic acid compositions for treating skin afflictions | |
| TW480178B (en) | Cosmetic compositions containing resveratrol | |
| US6054137A (en) | Promoting epidermal renewal with phloroglucinol | |
| TWI250025B (en) | Skin care composition | |
| US20030176366A1 (en) | Topical application of ascorbic acid compounds for augmenting the synthesis of epidermal ceramides | |
| JP2001517688A (en) | Use of ellagic acid and its derivatives in cosmetics and dermatology | |
| US20120189565A1 (en) | Skin clarifying complex, use of said complex, cosmestic or pharmaceutical composition comprising said complex and method for application thereof | |
| US20010046509A1 (en) | Use of cinnamic acid or of its derivatives in a cosmetic firming composition | |
| JP6282582B2 (en) | Use of zingerone or its derivatives to reduce or delay the signs of skin aging | |
| JPH0822813B2 (en) | Cosmetic composition for preventing skin aging | |
| US20070048243A1 (en) | Anti-aging composition containing criste marine and padina pavonica extracts | |
| JP2007051087A (en) | Collagen production promoter, skin care external preparation and oral medicine using the same | |
| JP2002308733A (en) | Method for reducing appearance of dark ciecles under eyes | |
| WO2024139786A1 (en) | Application of artemisia annua extract in preparation of anti-glycation product | |
| JP2013527190A (en) | Topical pharmaceutical or cosmetic composition useful for the treatment of diseases or conditions arising through corneal maturation defects | |
| JP2005263794A (en) | Collagen synthesis acceleration composition | |
| JP2005306806A (en) | Promoter of collagen synthesis and cosmetic for antiaging | |
| JPH09309813A (en) | Preparation for external use for skin | |
| US20180280287A1 (en) | Method and composition for a sacha inchi perennial plant extract based health and beauty aid | |
| JPH1135455A (en) | Collagen production promoter and skin lotion for preventing aging of skin or promoting healing of wound containing the same promoter | |
| US20040137023A1 (en) | 5-Cholesten-3beta, 25-diol-7-one, esters and ethers thereof, particularly for the treatment of dry skin and scalp | |
| JP4377266B2 (en) | Collagen synthesis promoter and anti-aging cosmetic | |
| JP3596953B2 (en) | Whitening cosmetics | |
| US20050281853A1 (en) | Skin compatible cosmetic compositions and delivery methods therefor | |
| JP2006232768A (en) | Atp production promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070302 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090330 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090519 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090901 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090910 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4377266 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120918 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120918 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150918 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |